Habek, M., Piskač, D., Gabelić, T., Barun, B., Adamec, I. & Krbot Skorić, M. (2022). Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis and Related Disorders, 62.. doi: 10.1016/j.msard.2022.103798
Habek, Mario, et al. "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab." Multiple Sclerosis and Related Disorders, vol. 62, 2022. https://doi.org/10.1016/j.msard.2022.103798
Habek, Mario, Dominik Piskač, Tereza Gabelić, Barbara Barun, Ivan Adamec and Magdalena Krbot Skorić. "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab." Multiple Sclerosis and Related Disorders 62 (2022). https://doi.org/10.1016/j.msard.2022.103798
Habek, M., et al. (2022) 'Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab', Multiple Sclerosis and Related Disorders, 62. doi: 10.1016/j.msard.2022.103798
Habek M, Piskač D, Gabelić T, Barun B, Adamec I, Krbot Skorić M. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis and Related Disorders [Internet]. 2022 June [cited 2024 November 23];62. doi: 10.1016/j.msard.2022.103798
M. Habek, D. Piskač, T. Gabelić, B. Barun, I. Adamec and M. Krbot Skorić, "Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab", Multiple Sclerosis and Related Disorders, vol. 62, June 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:571097. [Accessed: 23 November 2024]